Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.40 |
| ▸ | PPARD | Q03181 | 13/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854567 | 0.84 | FFAR1 (0.39) | PPARGPPARDFFAR1PPARA | |
| SCHEMBL5854871 | 0.83 | PPARG (0.41) | PPARGPPARDFFAR1PPARAESR1 | |
| SCHEMBL5857617 | 0.81 | PPARG (0.33) | PPARGPPARDFFAR1PPARAESR1 | |
| SCHEMBL2007995 | 0.80 | CYP3A4 (0.46) | PPARGPPARDFFAR1PPARAESR1 | |
| SCHEMBL5854096 | 0.75 | ROR1 (0.35) | ROR1 | |
| SCHEMBL5854607 | 0.74 | PTPN1 (0.36) | PPARGPPARDFFAR1PPARAPTPN1 | |
| SCHEMBL5854285 | 0.74 | PTPN1 (0.36) | PPARGPPARDFFAR1PPARAPTPN1 | |
| SCHEMBL5854043 | 0.73 | PTPN1 (0.37) | PPARGPPARDFFAR1PPARAPTPN1 | |
| SCHEMBL2742797 | 0.73 | CYP3A4 (0.43) | PPARGPPARDFFAR1ESR1ESR2 | |
| SCHEMBL7588340 | 0.72 | ESR1 (0.47) | PPARGPPARDFFAR1PPARAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| CN-1312803-A | Novel benzopyran or benzothiopyran derivatives | C & C RES LAB (KR) | 2001-09-12 | — | — | CN | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | PPARG 272/4885PPARD 138/4885FFAR1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.